SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. T...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/907a1035deb849e6a0068053d678c154 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:907a1035deb849e6a0068053d678c154 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:907a1035deb849e6a0068053d678c1542021-11-18T04:44:23ZSARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines1018-364710.1016/j.jksus.2021.101648https://doaj.org/article/907a1035deb849e6a0068053d678c1542021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1018364721003104https://doaj.org/toc/1018-3647SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These spike protein subunits enable viral attachment by binding to the host cell via ACE-2 (angiotensin converting enzyme-2) receptor, thus facilitating the infection. During viral entry, one of the key steps is the cleavage of the S1-S2 spike protein subunits via surface TMPRSS2 (transmembrane protease serine 2) and results in viral infection. Hence, the S-protein is critical for the viral attachment and penetration into the host. The rapid advancement of our knowledge on the structural and functional aspects of the spike protein could lead to development of numerous candidate vaccines against SARS-CoV2. Here the authors discuss about the structure of spike protein and explore its related functions. Our aim is to provide a better understanding that may aid in fighting against CoVID-19 and its treatment.Palaniyandi VelusamyKannan KirubaChia-Hung SuViswanathan ArunPeriasamy AnbuSubash C.B. GopinathBaskaralingam VaseeharanElsevierarticleCoronavirusSARS-CoV2Spike ProteinVirus EntryVaccineScience (General)Q1-390ENJournal of King Saud University: Science, Vol 33, Iss 8, Pp 101648- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Coronavirus SARS-CoV2 Spike Protein Virus Entry Vaccine Science (General) Q1-390 |
| spellingShingle |
Coronavirus SARS-CoV2 Spike Protein Virus Entry Vaccine Science (General) Q1-390 Palaniyandi Velusamy Kannan Kiruba Chia-Hung Su Viswanathan Arun Periasamy Anbu Subash C.B. Gopinath Baskaralingam Vaseeharan SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
| description |
SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These spike protein subunits enable viral attachment by binding to the host cell via ACE-2 (angiotensin converting enzyme-2) receptor, thus facilitating the infection. During viral entry, one of the key steps is the cleavage of the S1-S2 spike protein subunits via surface TMPRSS2 (transmembrane protease serine 2) and results in viral infection. Hence, the S-protein is critical for the viral attachment and penetration into the host. The rapid advancement of our knowledge on the structural and functional aspects of the spike protein could lead to development of numerous candidate vaccines against SARS-CoV2. Here the authors discuss about the structure of spike protein and explore its related functions. Our aim is to provide a better understanding that may aid in fighting against CoVID-19 and its treatment. |
| format |
article |
| author |
Palaniyandi Velusamy Kannan Kiruba Chia-Hung Su Viswanathan Arun Periasamy Anbu Subash C.B. Gopinath Baskaralingam Vaseeharan |
| author_facet |
Palaniyandi Velusamy Kannan Kiruba Chia-Hung Su Viswanathan Arun Periasamy Anbu Subash C.B. Gopinath Baskaralingam Vaseeharan |
| author_sort |
Palaniyandi Velusamy |
| title |
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
| title_short |
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
| title_full |
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
| title_fullStr |
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
| title_full_unstemmed |
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
| title_sort |
sars-cov-2 spike protein: site-specific breakpoints for the development of covid-19 vaccines |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/907a1035deb849e6a0068053d678c154 |
| work_keys_str_mv |
AT palaniyandivelusamy sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT kannankiruba sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT chiahungsu sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT viswanathanarun sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT periasamyanbu sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT subashcbgopinath sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT baskaralingamvaseeharan sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines |
| _version_ |
1718425115736145920 |